Clinician-reported changes in octreotide prescribing for malignant bowel obstruction as a result of an adequately powered phase III study: A transnational, online survey

SAGE Palliative Medicine & Chronic Care

This episode features Professor David Currow (University of Technology Sydney, Ultimo, NSW, Australia. Wolfson Palliative Care Research Centre, University of Hull, Hull, UK). This transnational online survey aimed to determine the impact of a phase III randomised controlled trial on palliative care clinicians’ self-reported practice change. The orginal study in question described the use of octreotide in the management of inoperable malignant bowel obstruction. This survey was distributed in 2016, 2 years after the first publication of the study in a peer-reviewed journal.The results demonstrated that out of 106 respondents, 52 (49.1%) indicated modified practice (60.9% of those who had previously prescribed octreotide in this setting). In those who reported practice change, most frequently octreotide was now used when other therapies failed. The results suggest that there is a cohort of ‘early adopters’ within palliative care practice as new evidence becomes available. Full paper available from: http://journals.sagepub.com/doi/abs/10.1177/0269216318778460?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed If you would like to record a podcast about your published (or accepted) Palliative Medicine paper, please contact Dr Amara Nwosu: [e-mail]